Tazemetostat is an orally taken investigational medicine that is the first of its kind targeting the EZH2 protein. The abnormal functioning of EZH2 has been implicated in a number of different cancers. Tazemetostat has demonstrated anti-tumor activity and has been generally well tolerated when used as an investigational treatment in clinical trials for several types of cancer. Tazemetostat is currently being studied in multiple clinical trials for both blood cancers and solid tumor cancers.
To connect with Epizyme and learn more about tazemetostat clinical trials please submit the following information.